The manufacturer of Savaysa (edoxaban) is Daiichi Sankyo [1]. Savaysa is an anticoagulant medication used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, and to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) [2].
What is edoxaban used for?
Edoxaban is prescribed to lower the risk of stroke and systemic embolism in individuals diagnosed with non-valvular atrial fibrillation. It is also used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) [2].
How does Savaysa work?
Savaysa functions by inhibiting Factor Xa, a crucial component in the blood clotting cascade. By blocking Factor Xa, edoxaban reduces thrombin generation, thereby preventing the formation of blood clots [3].
When was edoxaban approved?
Edoxaban received approval from the U.S. Food and Drug Administration (FDA) in December 2014 [4].
What are the side effects of Savaysa?
Common side effects associated with Savaysa include bleeding, bruising, and nausea [5]. More serious risks involve the possibility of major bleeding, which can be life-threatening [2]. Patients should be aware of signs of bleeding, such as unusual bruising, prolonged bleeding from cuts, nosebleeds, bleeding gums, or blood in urine or stool [5].
How does edoxaban compare to other anticoagulants?
Edoxaban is a direct oral anticoagulant (DOAC), a class that includes other medications like apixaban (Eliquis), rivaroxaban (Xarelto), and dabigatran (Pradaxa). These DOACs offer advantages over older anticoagulants like warfarin, such as a predictable dosing regimen and less need for routine blood monitoring [6]. Comparisons between specific DOACs often focus on efficacy in different patient populations, bleeding risk profiles, and drug-drug interaction potential [7].
What is the patent status of edoxaban?
Information regarding the specific patent expiry dates for edoxaban is typically found in pharmaceutical databases and legal filings. Patents for drugs are complex and can involve multiple patents covering different aspects of the drug, such as its composition, manufacturing process, and uses. Companies often seek to extend patent protection through various means, leading to litigation [8].
Who is Daiichi Sankyo?
Daiichi Sankyo is a global pharmaceutical company with its headquarters in Japan. It focuses on the research, development, manufacturing, and marketing of pharmaceutical products, including those for cardiovascular diseases, oncology, and pain management [1].